Sanofi

<div class="infobox infobox-company">
<div class="infobox-header">Sanofi</div>
<div class="infobox-row"><strong>Headquarters:</strong> Paris, France</div> [@clinicaltrialsgov]
<div class="infobox-row"><strong>Founded:</strong> 2004 (merger)</div> [@sanofia]
<div class="infobox-row"><strong>Market Cap:</strong> ~$125 billion (2024)</div> [@industry]
<div class="infobox-row"><strong>Ticker:</strong> SAN (Euronext), SNY (NASDAQ)</div>
<div class="infobox-row"><strong>Website:</strong> [sanofi.com](https://www.sanofi.com)</div>
</div>

Funding

• IPO: NYSE: SNY
• Market Cap: ~$130B (2026)
• 2025 Revenue: €45B
• 2024 Revenue: €43B
• R&D Investment: ~$7B annually

Overview

...

<div class="infobox infobox-company">
<div class="infobox-header">Sanofi</div>
<div class="infobox-row"><strong>Headquarters:</strong> Paris, France</div> [@clinicaltrialsgov]
<div class="infobox-row"><strong>Founded:</strong> 2004 (merger)</div> [@sanofia]
<div class="infobox-row"><strong>Market Cap:</strong> ~$125 billion (2024)</div> [@industry]
<div class="infobox-row"><strong>Ticker:</strong> SAN (Euronext), SNY (NASDAQ)</div>
<div class="infobox-row"><strong>Website:</strong> [sanofi.com](https://www.sanofi.com)</div>
</div>

Funding

• IPO: NYSE: SNY
• Market Cap: ~$130B (2026)
• 2025 Revenue: €45B
• 2024 Revenue: €43B
• R&D Investment: ~$7B annually

Overview

Sanofi is a French multinational pharmaceutical company with significant investments in neurodegenerative disease research. Through its neurology therapeutic area, Sanofi has pursued multiple approaches to treating Alzheimer's disease, Parkinson's disease, and multiple sclerosis. The company combines internal R&D capabilities with strategic partnerships to advance its neuroscience pipeline.

Alzheimer's Disease Pipeline

Anti-Amyloid Programs

| Compound | Mechanism | Phase | Status |
|----------|-----------|-------|--------|
| Aducanumab collaboration | Anti-amyloid antibody | Commercial | Partner: [Biogen](/companies/biogen) |

Sanofi had a collaboration agreement with Biogen for aducanumab development outside the United States, though the company has since shifted focus toward alternative mechanisms.

Tau Programs

Sanofi is exploring [tau](/proteins/tau)-targeting approaches for Alzheimer's disease and other tauopathies. These programs focus on:

• [Tau](/proteins/tau) aggregation inhibitors
• [Tau](/proteins/tau) immunotherapy
• Post-translational modification targets

Neuroinflammation

Sanofi's neuroinflammation research targets:

• [Microglia](/cell-types/microglia)l activation pathways
• [Complement system](/entities/complement-system) modulation
• Cytokine signaling in the CNS

Completed/Discontinued Programs

| Compound | Mechanism | Status |
|----------|-----------|--------|
| Verubecestat collaboration | BACE inhibitor | Discontinued (2018) |
| Lanabecestat collaboration | BACE inhibitor | Discontinued (2018) |

The BACE inhibitor programs were terminated following negative clinical trial results across the industry, leading Sanofi to pivot toward alternative therapeutic approaches.

Parkinson's Disease Programs

| Compound | Mechanism | Phase | Status |
|----------|-----------|-------|--------|
| Sarizotan | 5-HT1A agonist | Discontinued | - |
| Gene therapy programs | AAV-based delivery | Preclinical | Research |

Sanofi has explored multiple mechanisms for Parkinson's disease, including serotonin receptor modulation and gene therapy approaches for neuroprotection.

Multiple Sclerosis Programs

Sanofi's multiple sclerosis franchise represents a significant portion of its neuroscience business:

| Product | Mechanism | Status |
|---------|-----------|--------|
| Aubagio (teriflunomide) | Dihydroorotate dehydrogenase inhibitor | Commercial |
| Lemtrada (alemtuzumab) | Anti-CD52 antibody | Commercial |
| Mavenclad (cladribine) | Purine analog | Commercial |

Technology Platforms

Antibody Technologies

Sanofi leverages its global antibody engineering capabilities for CNS applications:

• Fully human antibody libraries
• Fc engineering for [blood-brain barrier](/entities/blood-brain-barrier) penetration
• Bispecific antibody platforms

Gene Therapy

Through its rare disease and neuroscience programs, Sanofi has developed gene therapy capabilities applicable to neurodegeneration:

• AAV vector design and manufacturing
• CNS-targeted delivery systems
• Regulatory expertise in gene therapies

Small Molecule Drug Discovery

Sanofi maintains robust small molecule capabilities:

• Structure-based drug design
• Phenotypic screening platforms
• CNS-penetrant chemistry expertise

Key Collaborations

Biogen Partnership

Sanofi and [Biogen](/companies/biogen) have collaborated on Alzheimer's disease programs, including commercial agreements for amyloid-targeting antibodies.

Academic Partnerships

Sanofi partners with leading neuroscience research institutions:

• Institut du Cerveau (Paris)
• Academic neuroscience centers globally
• Translational research networks

Biotech Collaborations

The company maintains active partnerships with biotechnology companies for:

• Early-stage target validation
• Platform technology access
• Co-development arrangements

Financial Information

• 2023 R&D Spending: €6.7 billion (company-wide)
• Neuroscience Focus: Core therapeutic area within pharmaceutical division
• Pipeline Investment: Continued commitment to neurodegeneration research

Key Personnel

• CEO: Paul Hudson
• Head of Research: Emmanuelle Charpentier
• Neuroscience Leadership: Dedicated therapeutic area team

Clinical Evidence

Sanofi's neurodegeneration programs have contributed to the field:

• Phase 3 data for MS therapies (supporting CNS drug development expertise)
• Biomarker development for neurodegeneration
• Combination therapy approaches

Competitive Positioning

Sanofi differentiates itself through:

European Base - Strong presence in European markets

Diversified Pipeline - Multiple mechanisms across neurodegeneration

MS Franchise - Established CNS commercial capabilities

Global Reach - Worldwide development and commercial infrastructure

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Biogen](/companies/biogen)
• [Multiple Sclerosis](/diseases/multiple-sclerosis)
• [Companies Index](/companies/index)

External Links

• [Sanofi Website](https://www.sanofi.com/)
• [ClinicalTrials.gov](https://clinicaltrials.gov)
• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)

References

Unknown, Sanofi Annual Report 2023 (2023)

Unknown, Sanofi Neuroscience Pipeline (n.d.)

Unknown, ClinicalTrials.gov - Sanofi Alzheimer's Studies (n.d.)

Unknown, Sanofi Multiple Sclerosis Products (n.d.)

Unknown, Industry Analysis of CNS Drug Development (n.d.)